Get the Stockscreener App
1.76
6.02%
0.10
After Hours:
1.75
-0.01
-0.57%
Neuronetics Inc stock is traded at $1.76, with a volume of 2.07M.
It is up +6.02% in the last 24 hours and up +41.94% over the past month.
Neuronetics Inc a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advance Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advance Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address the existing treatment options. The company operates in two segments: medical devices and clinic services.
See More
Previous Close:
$1.66
Open:
$1.66
24h Volume:
2.07M
Relative Volume:
1.02
Market Cap:
$122.47M
Revenue:
$151.64M
Net Income/Loss:
$-37.23M
P/E Ratio:
-3.2211
EPS:
-0.5464
Net Cash Flow:
$-13.58M
1W Performance:
+24.82%
1M Performance:
+41.94%
6M Performance:
-14.98%
1Y Performance:
-50.28%
1-Day Range:
$1.535
$1.825
1-Week Range:
$1.415
$1.825
52-Week Range:
$0.80
$4.8495
Neuronetics Inc Stock (STIM) Company Profile
Name
Neuronetics Inc
Sector
Industry
Phone
877-600-7555
Address
3222 PHOENIXVILLE PIKE, MALVERN, PA
Compare STIM vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
STIM
Neuronetics Inc
|
1.76 | 122.47M | 151.64M | -37.23M | -13.58M | -0.5464 |
ABT
Abbott Laboratories
|
93.93 | 163.61B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
329.78 | 126.42B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
83.87 | 107.36B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
44.77 | 66.54B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
92.21 | 53.09B | 6.30B | 1.07B | 1.09B | 1.8406 |
Neuronetics Inc Stock (STIM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-13-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-13-21 | Downgrade | BTIG Research | Buy → Neutral |
| Oct-13-21 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jan-22-21 | Upgrade | William Blair | Mkt Perform → Outperform |
| Feb-06-20 | Initiated | BTIG Research | Buy |
| Jul-24-18 | Initiated | Canaccord Genuity | Buy |
View All
Neuronetics Inc Stock (STIM) Latest News
What Does Jorey Chernett's Recent Buying Spree Signal for Neuronetics (STIM) - Kavout | AI
Neuronetics to Participate in a Panel Discussion at B. Riley Securities Mind, Muscle and Vision Summit on July 16, 2026 - marketscreener.com
Neuronetics to Participate at B. Riley Securities’ Mind, Muscle & Vision Summit - Quiver Quantitative
Neuronetics joins neuropsychiatry panel at B. Riley investor summit - Stock Titan
Neuronetics stock leans on its core therapy platform. - ad-hoc-news.de
STIM News | NEURONETICS INC (NASDAQ:STIM) - ChartMill
Neuronetics, Inc.(NasdaqGM: STIM) dropped from Russell 2000 Dynamic Index - marketscreener.com
Neuronetics, Inc.(NasdaqGM: STIM) dropped from Russell 3000E Index - marketscreener.com
Neuronetics, Inc.(NasdaqGM: STIM) dropped from Russell 2500 Index - marketscreener.com
Neuronetics, Inc.(NasdaqGM: STIM) dropped from Russell 2000 Index - marketscreener.com
Neuronetics, Inc.(NasdaqGM: STIM) dropped from Russell 3000E Growth Benchmark - marketscreener.com
Neuronetics, Inc.(NasdaqGM: STIM) dropped from Russell 3000 Growth Benchmark - marketscreener.com
Neuronetics, Inc. Actuals & Estimates (NASDAQ:STIM) - TradingView
Neuronetics Inc (STIM) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Price to book forward of Neuronetics, Inc. – NASDAQ:STIM - TradingView
Price to earnings forward of Neuronetics, Inc. – NASDAQ:STIM - TradingView
Enterprise value to EBITDA forward of Neuronetics, Inc. – NASDAQ:STIM - TradingView
Price to sales forward of Neuronetics, Inc. – NASDAQ:STIM - TradingView
STIM Forecast — Price Target — Prediction for 2027 - TradingView
A2JPMY Forecast — Price Target — Prediction for 2027 - TradingView
Neuronetics Inc (STIM) Institutional Confidence - TradingKey
Neuronetics, Inc. (STIM) Files 8-K Report: Company Details, Stock Info, and Compliance Data for June 2026 - Minichart
Form 8K Neuronetics Inc For: 23 June By Investing.com - Investing.com Nigeria
Cory Anderson named EVP, GM of Greenbrook at Neuronetics (NASDAQ: STIM) - Stock Titan
Neuronetics | 8-K: Current report - Moomoo
Neuronetics Inc (STIM) Valuation: PE, PB & Fair Value Analysis - TradingKey
Neuronetics Inc (STIM) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Neuronetics Inc (STIM) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Neuronetics Inc (STIM) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Neuronetics Inc (STIM) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Neuronetics Inc (STIM) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Neuronetics Inc (STIM) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Neuronetics (NASDAQ: STIM) director reallocates 42,500 shares to Madryn funds - Stock Titan
Madryn funds (NASDAQ: STIM) reallocate 72,500 Neuronetics RSU shares - Stock Titan
Neuronetics Names Sales Chief, Grants Equity Incentive - MyChesCo
STIM (NASDAQ) affiliate files to sell 42,164 vested shares via Fidelity - Stock Titan
STIM Technical Analysis | Trend, Signals & Chart Patterns | NEURONETICS INC (NASDAQ:STIM) - ChartMill
Neuronetics names Robert Greene as senior VP, sales - Medical Buyer
Neuronetics largest shareholder pushes for strategic review - Investing.com
Neuronetics Appoints Robert Greene as Senior Vice President Sales - The Globe and Mail
New Neuronetics sales chief gets 200,000-share stock grant - Stock Titan
Neuronetics Highlights Continued Advancements in TMS Research at CTMSS 2026 - The Manila Times
New TMS data on teen and adult depression at CTMSS 2026 - Stock Titan
Neuronetics, Inc. (STIM) Submits Form 8-K Reporting Shareholder Vote Results – Key Filing Details and Company Information - Minichart
STIM Q1 2026 Earnings: Narrower-Than-Expected Loss Signals Operational DisciplineNegative Surprise Momentum - dars.gov.et
Neuronetics Inc. (STIM) Holds Steady at $1.54 as Support and Resistance Define Trading RangeBreak of Structure - dars.gov.et
Neuronetics (STIM) director Megan Rosengarten granted 30,000 RSUs, now holds 170,890 shares - Stock Titan
Director at Neuronetics (STIM) receives 30,000-share RSU grant - Stock Titan
Neuronetics (STIM) director awarded 30,000 RSUs vesting by 2027 - Stock Titan
Neuronetics (STIM) director Sheryl Conley awarded 30,000 RSUs in stock grant - Stock Titan
Neuronetics (STIM) director granted 36,250 RSUs, holdings rise to 625,017 shares - Stock Titan
Neuronetics Inc Stock (STIM) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.36%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):